Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 839

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 839
---
 share of Company common stock outstanding immediately prior to the Merger, (ii) each then-outstanding Company stock option was assumed and converted into an option to purchase shares of Kintara common stock subject to certain adjustments based on the exchange ratio as set forth in the Merger Agreement, and (iii) each then-outstanding warrant to purchase shares of Company Common Stock was assumed and converted into and exchangeable based on the exchange ratio for a warrant of like tenor entitling the holder to purchase shares of Kintara common stock. F-82

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

The Merger is accounted for as a reverse recapitalization. Immediately after the merger, there were 42,032,165shares of the Company’s common stock outstanding. The following table shows the net liabilities assumed in the merger:

|                                                             |     | October 18,2024 |            |   |
|:------------------------------------------------------------|:----|:----------------|-----------:|:--|
| Cash and cash equivalents                                   |     | $               |     70,097 |   |
| Prepaid and other assets                                    |     |                 |    370,030 |   |
| Accounts payable and accrued expenses                       |     |                 | (1,787,039 | ) |
| Total net liabilities assumed                               |     |                 | (1,346,912 | ) |
| Plus: merger transaction costs                              |     |                 | (4,129,663 | ) |
| Total net liabilities assumed plus merger transaction costs |     | $               | (5,476,575 | ) |

Accounting treatment on the Contingent Value Rights “CVR” agreement

Based on management’s analysis, the CVRs were identified as freestanding financial instruments and determined to be indexed to Kintara’s own stock, as they are to be settled in Kintara Common Stock. Further, the CVR financial instruments are not mandatorily redeemable as the instruments do not require Kintara to redeem them for cash or other assets at a fixed or determinable date, or upon an event that is certain to occur and the CVRs do not represent an unconditional obligation requiring Kintara to redeem the instruments. The CVRs do not represent outstanding shares of Kintara Common Stock, and the CVRs do not obligate Kintara to buy back some or